RT Journal Article
SR Electronic
T1 Efficacy and Safety of Antibiotic Agents in Children with COVID-19: A Rapid Review
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.13.20064402
DO 10.1101/2020.04.13.20064402
A1 Wang, Jianjian
A1 Tang, Yuyi
A1 Ma, Yanfang
A1 Zhou, Qi
A1 Li, Weiguo
A1 Baskota, Muna
A1 Yang, Yinmei
A1 Wang, Xingmei
A1 Li, Qingyuan
A1 Luo, Xufei
A1 Fukuoka, Toshio
A1 Ahn, Hyeong Sik
A1 Lee, Myeong Soo
A1 Luo, Zhengxiu
A1 Liu, Enmei
A1 Chen, Yao-long
A1 on behalf of COVID-19 evidence and recommendations working group
YR 2020
UL http://medrxiv.org/content/early/2020/04/17/2020.04.13.20064402.abstract
AB Background The aim of this review was to evaluate the efficacy and safety of antibiotic agents in children with COVID-19, as well as to introduce the present situation of antibiotics use and bacterial coinfections in COVID-19 patients.Methods We searched Cochrane library, Medline, Embase, Web of Science, CBM, Wanfang Data and CNKI from their inception to March 31, 2020. In addition, we searched related studies on COVID-19 published before March 31, 2020 through Google Scholar. We evaluated the risk of bias of included studies, and synthesized the results using a qualitative synthesis.Results Six studies met our inclusion criteria. Five studies on SARS showed an overall risk of death of 7.2% to 20.0%. One study of SARS patients who used macrolides, quinolones or beta lactamases showed that the mean duration of hospital stay was 14.2, 13.8 and 16.2 days, respectively, and their average duration of fever was 14.3, 14.0 and 16.2 days, respectively. One cohort study on MERS indicated that macrolide therapy was not associated with a significant reduction in 90-day mortality (adjusted odds ratio [OR] 0.84, 95% confidence interval [CI] 0.47-1.51, P = 0.56) and improvement in MERS-CoV RNA clearance (adjusted hazard ratio [HR] 0.88, 95% CI 0.47, -1.64], P = 0.68). According to the findings of 33 studies, the proportion of antibiotics use ranged from 19.4% to 100.0% in children and 13.2% to 100.0% in adults, despite the lack of etiological evidence. The most commonly used antibiotics in adults were quinolones, cephalosporins and macrolides and in children meropenem and linezolid.Conclusions The benefits of antibiotic agents for adults with SARS or MERS were questionable in the absence of bacterial coinfections. There is no evidence to support the use of antibiotic agents for children with COVID-19 in the absence of bacterial coinfection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Clinical Research Center for Child Health and Disorders (Children’s Hospital of Chongqing Medical University, Chongqing, China) (grant number NCRCCHD-2020-EP-01) to [Enmei Liu]; Special Fund for Key Research and Development Projects in Gansu Province in 2020, to [Yaolong Chen]; The fourth batch of “Special Project of Science and Technology for Emergency Response to COVID-19” of Chongqing Science and Technology Bureau, to [Enmei Liu]; Special funding for prevention and control of emergency of COVID-19 from Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province (grant number No. GSEBMKT-2020YJ01), to [Yaolong Chen].Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study is a rapid review based on the original researches. All the data are from the existing studies and are true.